SD HEALTHCARERecent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
Scripps Health and SCAN Health Plans have entered into a co-branding agreement to explore and develop new products and services designed to serve the growing senior population, the organizations announced.
San Diego-based bioTheranostics Inc., a provider of genomic cancer diagnostic solutions, said it signed a contract with FedMed Inc., based in Maryland and one of the largest preferred provider organizations in the nation.
San Diego-based MabVax Therapeutics Inc., a privately held cancer immunotherapy company, and Telik Inc., a publicly traded clinical-stage oncology drug development company, have finalized their merger.
Peter Beetham has taken the CEO’s job at Cibus, the Mira Mesa-based biotech announced July 8.
Property was 93 percent occupied when it was sold.
Financing could help fund global marketing.
Move comes after one year of being a public company.
Diazyme Laboratories is part of General Atomics.
Biopharmaceutical company Cidara Therapeutics Inc. completed a $32 million Series A financing round, the company said.
Seragon Pharmaceuticals, a privately held San Diego-based drug developer targeting breast cancer treatment, agreed to be acquired by Genentech, a subsidiary of the Roche Group, for $725 million in cash plus future payments which could reach $1 billion if specific milestones are reached, the companies announced.
Scripps Health announced the opening of the Leichtag Foundation Critical Care Pavilion, which includes a new emergency department and inpatient rooms at Scripps Memorial Hospital Encinitas.
Trovagene Inc., a San Diego molecular diagnostics company, said it secured an unrestricted debt facility of $15 million from Silicon Valley bank and Oxford Finance LLC.
Cidara Therapeutics, a privately held bio-pharmaceutical company formerly known as K2 Therapeutics, said it completed a $32 million Series A financing round.
La Jolla-based biotech Ambrx Inc. withdrew its plans for an initial public offering, citing current market conditions, according to Renaissance Capital.
Palomar Health has named Robert Hemker as its new president and chief executive officer.